Beijing Balance Medical Technology Co.,Ltd. (SHA:688198)
China · Delayed Price · Currency is CNY 72.61
+0.61 (0.85%)
At close: Sep 18, 2026
SHA:688198 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 10,002 | 14,740 | 14,977 | 17,008 | 17,502 | 24,524 | |
Market Cap Growth | -35.83% | -1.58% | -11.94% | -2.82% | -28.63% | 228.95% |
Enterprise Value | 9,658 | 14,479 | 14,590 | 16,535 | 16,744 | 23,773 |
Last Close Price | 72.61 | 106.04 | 107.20 | 121.57 | 125.36 | 176.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 59.99 | 76.15 | 102.35 | 147.63 | 183.98 | 479.01 |
Forward PE | - | 64.08 | 72.92 | 89.59 | 104.25 | 238.22 |
PS Ratio | 15.98 | 23.77 | 29.84 | 45.89 | 59.30 | 97.39 |
PB Ratio | 8.08 | 11.23 | 11.98 | 14.31 | 15.92 | 24.82 |
P/TBV Ratio | 9.26 | 12.83 | 13.34 | 15.68 | 16.57 | 25.92 |
P/FCF Ratio | 779.44 | 239.31 | - | 1356.96 | 728.83 | 5741.55 |
P/OCF Ratio | 81.31 | 74.53 | 109.94 | 120.49 | 135.83 | 320.60 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 15.43 | 23.35 | 29.07 | 44.61 | 56.73 | 94.41 |
EV/EBITDA Ratio | 50.01 | 64.43 | 96.24 | 149.37 | 190.74 | 656.86 |
EV/EBIT Ratio | 65.11 | 77.59 | 110.65 | 166.17 | 203.78 | 787.92 |
EV/FCF Ratio | 752.64 | 235.06 | - | 1319.18 | 697.26 | 5565.71 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.05 | 0.07 | 0.01 | 0.01 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.31 | 0.41 | 0.06 | 0.11 | 0.02 | 0.04 |
Debt / FCF Ratio | 4.62 | 1.52 | - | 0.98 | 0.06 | 0.39 |
Net Debt / Equity Ratio | -0.26 | -0.38 | -0.29 | -0.44 | -0.56 | -0.78 |
Net Debt / EBITDA Ratio | -1.75 | -2.23 | -2.38 | -4.73 | -6.97 | -21.29 |
Net Debt / FCF Ratio | -25.60 | -8.13 | 13.33 | -41.75 | -25.46 | -180.42 |
Asset Turnover | 0.43 | 0.41 | 0.36 | 0.30 | 0.27 | 0.27 |
Inventory Turnover | 0.83 | 1.11 | 1.34 | 1.13 | 1.17 | 1.55 |
Quick Ratio | 4.30 | 3.57 | 4.45 | 7.75 | 10.66 | 22.23 |
Current Ratio | 5.33 | 3.98 | 5.17 | 8.43 | 11.45 | 23.31 |
Return on Equity (ROE) | 12.78% | 14.02% | 10.84% | 9.56% | 9.04% | 5.62% |
Return on Assets (ROA) | 6.37% | 7.64% | 5.98% | 4.96% | 4.65% | 1.98% |
Return on Invested Capital (ROIC) | 12.78% | 19.11% | 14.86% | 15.73% | 20.72% | 20.70% |
Return on Capital Employed (ROCE) | 11.20% | 13.40% | 10.00% | 8.00% | 7.40% | 3.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.66% | 1.31% | 0.98% | 0.68% | 0.54% | 0.21% |
FCF Yield | 0.13% | 0.42% | -0.18% | 0.07% | 0.14% | 0.02% |
Dividend Yield | 1.10% | 0.75% | 0.75% | 0.66% | 0.40% | 0.20% |
Payout Ratio | 67.35% | 57.26% | 74.67% | 58.88% | 50.69% | 37.51% |
Buyback Yield / Dilution | 0.39% | -0.39% | 0.29% | -0.92% | -0.86% | -0.44% |
Total Shareholder Return | 1.49% | 0.37% | 1.03% | -0.27% | -0.46% | -0.24% |